Trial Profile
ACNS0821 - Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC 704865, BB-IND 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Temozolomide (Primary)
- Indications Medulloblastoma; Primitive neuroectodermal tumours
- Focus Therapeutic Use
- 01 Jul 2021 Status changed from active, no longer recruiting to completed.
- 11 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 1 Mar 2018.
- 16 Jun 2016 Planned primary completion date changed from 1 Sep 2021 to 1 Jun 2017.